Key takeaways
Dulera (mometasone/formoterol) is a brand-name prescription combination inhaler for asthma.
Although its patent expired in 2020, a generic version of Dulera is not yet available.
Talk to your healthcare provider about ways to save, including switching from Dulera to other medications or using coupons to make your treatment more affordable.
Dulera (mometasone furoate and formoterol fumarate dihydrate aerosol) is a prescription maintenance inhaler used to help control asthma symptoms. The Food and Drug Administration (FDA) has approved it for the treatment of asthma in people 5 years and older. Without insurance, Dulera costs about $499 for one 13 g of 200-5 mcg/ACT inhaler, typically a one-month supply. This monthly cost can add up for people managing their asthma long-term, which is why some may consider generic medications that can be up to 85% more affordable than brand-name drugs.
Is there a generic for Dulera?
There’s currently no generic version of the brand-name drug Dulera. It’s a combination inhaler that contains the inhaled corticosteroid (ICS) mometasone and long-acting beta agonist (LABA) formoterol. There are generic versions of certain other inhalers that contain an ICS and a LABA, though, such as Symbicort and Advair, although the ingredients are not exactly the same as those of Dulera.
Why isn’t there a Dulera generic yet?
There are a few reasons why there aren’t any Dulera generics available. First, Dulera has been protected by a combination of patents and regulatory exclusivity since its approval in 2010. Patents are property rights granted by the U.S. Patent and Trademark Office, often lasting 20 years from the date of filing. They can cover the formulations of the drug and the way it’s delivered. Separately, the FDA may give exclusivity, which blocks generic competitors for a period of time. Exclusivity can last several years, but patents can last longer. In Dulera’s case, its patents and exclusivity have expired since 2020. Generic manufacturers are still in the process of developing and getting approval for generic mometasone-formoterol.
Dulera is a combination of two active ingredients plus a delivery device. To get FDA approval, a generic version would need to prove it delivers the medication to the lungs in the same way as brand-name Dulera. That includes matching factors like the way it sprays, particle size, and consistency of each dose. While medications in pill form often have generics within a few years of patent expiration, inhalers may take longer to reach the market because of these unique challenges.
Dulera alternatives
Besides Dulera, there are alternative options that your healthcare provider may consider to help manage your asthma symptoms. Elizabeth Rubin Ribak, MD, clinical adviser at Embers Recovery in Phoenix, Arizona, says, “Dulera is meant for maintenance therapy to help prevent symptoms like wheezing, coughing, and shortness of breath.” It’s a maintenance medication, and “not a rescue inhaler and should not be used for sudden asthma attacks,” she explains.
Elizabeth Moffett, registered respiratory therapist (RRT) and expert adviser for Omhale, says that since Dulera is a combination therapy that contains an ICS and a LABA, it is more convenient than separate ICS and LABAs. She says that fewer steps equals better patient adherence to the medication. Other combination medications include Advair (fluticasone/salmeterol) Diskus and HFA, which have a generic version of fluticasone-salmeterol.
Symbicort (budesonide-formoterol) is another ICS/LABA combination medicine that’s approved for asthma in children and adults 6 and older and chronic obstructive pulmonary disease (COPD). “Compared to other asthma inhalers, Dulera is similar to Advair and Symbicort, but Dulera uses formoterol, which acts more quickly, thus it can begin easing breathing sooner while still providing long-term control,” Dr. Rubin Ribak shares.
Dulera is prescribed for people when an ICS alone isn’t able to manage their asthma symptoms. Examples of ICS drugs include Asmanex (mometasone furoate), Flovent (fluticasone propionate), and Pulmicort (budesonide).
In certain cases, healthcare providers may consider triple therapy to control someone’s asthma symptoms. Triple therapy combines an ICS, LABA, and a long-acting muscarinic antagonist (LAMA) for severe respiratory symptoms. Trelegy Ellipta (fluticasone-vilanterol-umeclidinium) and Breztri Aerosphere (budesonide-glycopyrrolate-formoterol fumarate) are examples of triple therapy drugs, but only Trelegy Ellipta is approved to treat asthma in addition to COPD symptoms.
Don’t switch medications without medical advice. Consult with your healthcare provider to learn more about alternative treatments for your asthma symptoms. They can help you understand your options and choose one that works for you.
How to save on Dulera
There are several ways to save on brand-name Dulera until a generic becomes available.
1. Use a SingleCare coupon
If you’re not using your insurance benefits, a SingleCare coupon can help you save on the cash price of Dulera. The average price of Dulera without insurance is $499 per 13 g of 200-5 mcg/ACT inhaler. With a SingleCare coupon, you may pay as low as $337, depending on your choice of pharmacy, saving over $1,800 per year.
SingleCare coupons are free and are accepted at many retail pharmacies. To get a Dulera coupon, select the pharmacy where you want to use your coupon, download the coupon, and show it to the pharmacy staff. Members save even more, and it’s free to sign up.
Get your free prescription discount card
2. Explore alternatives with your healthcare provider
A Dulera generic isn’t available yet, but there are other alternatives to Dulera that can be more affordable, covered by your insurance plan, or have a generic equivalent. For example, Advair Diskus has a generic fluticasone-salmeterol, also marketed as Wixela Inhub. The average cost of brand-name Advair Diskus is $502 per 60-dose inhaler, while its generic can cost as low as $50 per 60-dose inhaler with a SingleCare coupon.
Symbicort is another combination inhaler your healthcare provider may consider. On average, it can cost $478 per 10.2 g of 160-4.5 mcg/ACT inhaler, but it can cost as low as $156 if you use a generic version, such as Breyna, with a SingleCare coupon.
3. Medicare or Medicaid coverage
Some Medicare Part D and Medicaid plans may cover Dulera. Many state Medicaid plans offer copays under $10 for brand-name medications. For example, New York State’s Medicaid drug list includes Dulera as a Tier 2 brand-name drug, although it will need prior authorization. People with this plan can expect to pay between $1 and $3 for brand-name drugs.
If you have Medicare or Medicaid, you can contact your plan administrators to find out whether you have Dulera coverage.
4. Use a manufacturer’s coupon
Check with the manufacturer, Organon, to see whether you’re eligible for its savings offer, which helps people with private insurance plans reduce their out-of-pocket costs. To be eligible, you must have private insurance coverage (excluding Medicare, Medicaid, or other government health programs), be 18 years or older, and live in the United States or Puerto Rico. You can only use the coupon 12 times, and you can save a maximum of $90 per prescription.
Bottom line
A generic version of Dulera isn’t available yet, but generic manufacturers are working to make it available in the future. Until then, there are ways to save on Dulera if long-term cost becomes an issue. You can also talk to your healthcare provider about alternative options, such as generic Symbicort or generic Advair, to help manage your asthma symptoms.
The SingleCare prices in this article are the most accurate at the time of publishing in ZIP code 23666 as of Dec. 9, 2025. Prices vary by pharmacy. Visit our Dulera coupon page for updated Dulera prices near you.
- Dulera – mometasone furoate and formoterol fumarate dihydrate aerosol, DailyMed (2025)
- Drug approval package Dulera, Food and Drug Administration (2013)
- Frequently asked questions on patents and exclusivity, Food and Drug Administration (2020)
- Orange Book: Approved drug products with therapeutic equivalence evaluations Dulera, Food and Drug Administration
- The top 10 drugs losing US exclusivity in 2024, Fierce Pharma (2024)
- Symbicort – budesonide and formoterol fumarate dihydrate aerosol, DailyMed (2019)
- Trelegy Ellipta – fluticasone furoate, umeclidinium bromide and vilanterol trifenatate powder, DailyMed (2023)
- Preferred drug list (PDL) New York Essential Plan, UnitedHealthcare (2024)
- Benefits and coverage, New York State Department of Health